Supportive management strategies for disseminated intravascular coagulation

Summary

The cornerstone of the management of disseminated intravascular coagulation (DIC) is the treatment of the underlying condition triggering the coagulopathy. However, a number of uncertainties remain over the optimal supportive treatment. The aim of this study was to provide evidence and expert-based recommendations on the optimal supportive haemostatic and antithrombotic treatment strategies for patients with DIC. A working group defined five relevant clinical scenarios. Published studies were systematically searched in the MEDLINE and EMBASE databases (up to May 2014). Seven internationally recognised experts were asked to independently provide clinical advice. A two-phase blinded data collection technique was used to reach consensus. Only three randomised controlled trials (RCTs) on the supportive management of DIC were identified. The RCTs (overall less than 100 patients) investigated the use of fresh frozen plasma and platelet transfusion and found no differences in survival between the intervention and control groups. The experts’ approach was heterogeneous, although there was consensus that supportive management should vary according to the underlying cause, clinical manifestations and severity of blood test abnormalities. Platelet transfusion should be given to maintain platelet count > 50×10⁹/l in case of bleeding while a lower threshold of 20 to 30×10⁹/l may be used in DIC without bleeding. Thromboprophylaxis with low-molecular-weight heparin is advised until bleeding ensues or platelet count drops below 30×10⁹/l. In conclusion, in the absence of solid evidence from RCTs, an individualised supportive management of DIC is advisable based on the type of underlying disease, presence of bleeding or thrombotic complications and laboratory tests results.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Disseminated intravascular coagulation (DIC) - prophylaxis - venous thrombosis - fresh frozen plasma - platelet transfusion

• References

• 1 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
• 2 Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care 2014; 2: 15.
• 3 Di Nisio M, Baudo F, Cosmi B. et al. Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2012; 129: e177-e184.
• 4 Wada H, Thachil J, Di Nisio M. et al. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 761-767.
• 5 Ageno W, Dentali F, Squizzato A. et al. Evidence and clinical judgment: Treatment of cerebral vein thrombosis. Thromb Haemost 2010; 103: 1109-1115.
• 6 Stanworth SJ, Brunskill Sj, Hyde CJ. et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004; 126: 139-152.
• 7 Kumar A, Mhaskar R, Grossman BJ. et al. on behalf of AABB Platelet Transfusion Guidelines Panel. Platelet transfusion: a systematic review of the clinical evidence. Transfusion 2015; 55: 1116-1127.
• 8 Gross SJ, Filston HC, Anderson JC. Controlled study of treatment for disseminated intravascular coagulation in the neonate. J Pediatr 1982; 100: 445-448.
• 9 Beck KH, Mortelsmans Y, Kretschmer VV. et al. Comparison of solvent/detergent- inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusionsther Transfusionsmed 2000; 27: 144-148.
• 10 Müller MC, Arbous MS, Spoelstra-de Man AM. et al. Transfusion of freshfrozen plasma in critically ill patients with a coagulopathy before invasive procedures: a randomized clinical trial. Transfusion 2015; 55: 26-35.
• 11 Wiedermann CJ, Kaneider NC. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul Fibrinolysis 2006; 17: 521-526.
• 12 Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med 2014; 370: 847-859.
• 13 Kienast J, Juers M, Wiedermann CJ. et al. for the KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4: 90-97.